Class summary at a glance.

Every drug in the Serotonin-3 Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 6tracked in Part D
CY24 Part D spend: $244.9Mcombined across class
Total Rx claims: 14.1M8.5M unique beneficiaries
Generic mfrs (active): 49across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Ondansetron

Brand: ONDANSETRON · 14.1M Part D claims (CY24) · 8.5M beneficiaries · First FDA approval: 2006-11-07

19 generic mfrs 1312 plans require PA

Low NADAC$0.064

→

Avg plan cost$0.143

Part D spend $218.9M 2× spread, current vs floor

Class share

89%

of class CY24 spend

View profile →

Alosetron

Brand: LOTRONEX · 20K Part D claims (CY24) · 5K beneficiaries · First FDA approval: 2015-05-26

4 generic mfrs 416 plans require PA

Low NADAC$2.22

→

Avg plan cost$3.03

Part D spend $14.6M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Granisetron

Brand: Granisetron · 18K Part D claims (CY24) · 7K beneficiaries · First FDA approval: 2009-06-22

13 generic mfrs 239 plans require PA

Low NADAC$1.10

→

Avg plan cost$84.55

Part D spend $11.1M 77× spread, current vs floor

Class share

of class CY24 spend

View profile →

Palonosetron

Brand: Palonosetron · 7K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2018-03-23

13 generic mfrs Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $409092

Class share

of class CY24 spend

View profile →

Fosnetupitant and Palonosetron

Brand: AKYNZEO · — Part D claims (CY24) · First FDA approval: 2018-04-20

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Netupitant and Palonosetron

Brand: AKYNZEO · — Part D claims (CY24) · First FDA approval: 2014-10-13

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.